CABOMETYX is now approved in patients who have received prior therapy* for advanced renal cell carcinoma (RCC)1
*Anti-angiogenic therapy.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Category 1 Recommendation2
Cabozantinib (CABOMETYXTM) has a Category 1 recommendation for patients with advanced clear cell histology RCC after prior anti-angiogenic therapy.
CABOMETYXTM is the only single agent to demonstrate significant improvement across 3 endpoints—overall survival (OS), progression-free survival (PFS), and objective response rate (ORR)—in advanced RCC after prior treatment1*
*Anti-angiogenic therapy.
Based on the results of the METEOR trial,1 the NCCN Guidelines® include cabozantinib (CABOMETYXTM) as a Category 1 subsequent therapy option in patients with advanced clear cell RCC who have been previously treated with anti-angiogenic therapy, and note that eligible patients should preferentially receive it over everolimus.2
QUICK START PROGRAM
Eligible patients receive a 15-day supply at no cost
- Available for new patients who experience a delay of more than 5 days in the processing or approval of their prescription for CABOMETYX™
COMPANY:
Exelixis®
PHARMACOLOGIC CLASS:
Receptor tyrosine kinase inhibitor